The Oncology Institute, Inc. (TOI)
| Market Cap | 584.90M +183.2% |
| Revenue (ttm) | 545.76M +35.4% |
| Net Income | -36.32M |
| EPS | -0.37 |
| Shares Out | 99.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,992,544 |
| Open | 5.64 |
| Previous Close | 5.65 |
| Day's Range | 5.59 - 6.11 |
| 52-Week Range | 2.32 - 6.11 |
| Beta | 0.39 |
| Analysts | Strong Buy |
| Price Target | 8.20 (+40.17%) |
| Earnings Date | Aug 12, 2026 |
About TOI
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliativ... [Read more]
Financial Performance
In 2025, The Oncology Institute's revenue was $502.73 million, an increase of 27.79% compared to the previous year's $393.41 million. Losses were -$50.31 million, -5.09% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for TOI stock is "Strong Buy." The 12-month stock price target is $8.2, which is an increase of 40.17% from the latest price.
News
Oncology Institute price target raised to $9 from $8 at BTIG
BTIG raised the firm’s price target on Oncology Institute (TOI) to $9 from $8 and keeps a Buy rating on the shares. The firm maintains the name as a Top…
The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidity
CERRITOS, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, announced today that it has...
Oncology Institute initiated with a Buy at Lake Street
As previously reported, Lake Street initiated coverage of Oncology Institute (TOI) with a Buy rating and $10 price target With many recently approved cancer drugs still ramping and numerous promising…
Oncology Institute initiated with a Buy at Lake Street
Lake Street initiated coverage of Oncology Institute (TOI) with a Buy rating and $10 price target
Oncology Institute price target raised to $7 from $5 at Needham
Needham raised the firm’s price target on Oncology Institute (TOI) to $7 from $5 and keeps a Buy rating on the shares after hosting a meeting with its management team.
Oncology Institute price target raised to $8 from $7 at BTIG
BTIG analyst David Larsen raised the firm’s price target on Oncology Institute (TOI) to $8 from $7 and keeps a Buy rating on the shares after hosting a virtual roadshow…
Topicus.com Inc. Announces a Revised Proposal to Acquire ReadyTech
TORONTO, May 31, 2026 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV: TOI), acting through its subsidiary TSS Europe B.V. (“TSS”), today submitted a revised non-binding indicative proposal to acquire Read...
The Oncology Institute Chief Medical Officer to Speak on Value-Based Specialty Care at APG Spring Conference
CERRITOS, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Yale D.
The Oncology Institute Slides: Investor presentation
The Oncology Institute has posted slides in relation to its latest quarterly earnings report, which was published on May 20, 2026.
The Oncology Institute to Participate in B. Riley Securities Institutional Investor Conference
CERRITOS, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Dr. Daniel Virn...
The Oncology Institute Earnings Call Transcript: Q1 2026
Q1 2026 saw 41% revenue growth, record specialty pharmacy performance, and profitability in Florida. Guidance for revenue, adjusted EBITDA, and free cash flow was reaffirmed or raised, with ongoing expansion in value-based contracts and AI-driven efficiencies.
The Oncology Institute Quarterly report: Q1 2026
The Oncology Institute has published its Q1 2026 quarterly earnings report on May 7, 2026.
The Oncology Institute Earnings release: Q1 2026
The Oncology Institute released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
The Oncology Institute Reports First Quarter 2026 Financial Results
CERRITOS, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, t...
Constellation Software Inc. and Topicus.Com Inc. Announce Results for Topicus.com Inc. for the First Quarter Ended March 31, 2026
TORONTO, May 05, 2026 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV:TOI) in a joint release with Constellation Software Inc. (TSX:CSU) today announced financial results for Topicus.com Inc. (“Topicus” or...
The Oncology Institute Proxy statement: Proxy filing
The Oncology Institute filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
The Oncology Institute Proxy statement: Proxy filing
The Oncology Institute filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
The Oncology Institute Announces First Quarter 2026 Earnings Release Date and Conference Call
CERRITOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI) a pioneer in value-based community oncology care, today announced that the company will release ...
The Oncology Institute Transcript: 25th Annual Needham Virtual Healthcare Conference
A value-based oncology provider is expanding rapidly through delegated contracts, especially in Florida, and expects significant growth in capitated revenue and profitability through 2028. The dispensary segment has become the largest revenue driver, and AI initiatives are set to enhance efficiency and margins.
Oncology Institute names Minh Merchant Chief Legal Officer
The Oncology Institute (TOI) announced that Minh Merchant has joined the organization as Chief Legal Officer. In this role, Merchant will oversee legal, regulatory, compliance and privacy functions as...
Oncology Institute price target raised to $8 from $6 at B. Riley
B. Riley raised the firm’s price target on Oncology Institute (TOI) to $8 from $6 and keeps a Buy rating on the shares. Oncology Institute delivered its first profitable quarter…
The Oncology Institute Slides: Investor presentation
The Oncology Institute has posted slides in relation to its latest quarterly earnings report, which was published on March 13, 2026.
The Oncology Institute Earnings Call Transcript: Q4 2025
Achieved first profitable quarter on adjusted EBITDA in Q4 2025, with revenue up 28% year-over-year and strong growth in pharmacy and capitated care. 2026 guidance projects continued revenue and margin expansion, with positive free cash flow expected by year-end.
The Oncology Institute Annual report: Q4 2025
The Oncology Institute has published its Q4 2025 annual report on March 12, 2026.
The Oncology Institute Earnings release: Q4 2025
The Oncology Institute released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.